Last reviewed · How we verify
NCT01159964
Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery
Phase 1 trial testing Immunotherapeutic GSK2302032A, different formulations in Lung Cancer, Non-Small Cell in 60 participants. Terminated before completion.
19 October 2011
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 20 July 2010 |
| Primary completion | 19 October 2011 |
| Estimated completion | 10 September 2014 |
| Sites | 37 locations across France, Italy, Russia, Germany, Poland, United States |
Drugs / interventions tested
- Immunotherapeutic GSK2302032A, different formulations — full drug profile →
Conditions studied
- Lung Cancer, Non-Small Cell — all drugs for Lung Cancer, Non-Small Cell →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
18 and older, any sex, with Lung Cancer, Non-Small Cell. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review.
Kaczmarek M, Poznańska J, Fechner F, Michalska N, et al · · 2023 · cited 135× · PMID 37681891 · DOI 10.3390/cells12172159 -
Antigen-specific vaccines for cancer treatment.
Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, et al · · 2014 · cited 109× · PMID 25483639 · DOI 10.4161/21645515.2014.973317 -
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Al-Khadairi G, Decock J. · · 2019 · cited 85× · PMID 31311081 · DOI 10.3390/cancers11070984 -
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study.
Pujol JL, De Pas T, Rittmeyer A, Vallières E, et al · · 2016 · cited 64× · PMID 27544054 · DOI 10.1016/j.jtho.2016.08.120 -
Cancer/testis antigens and urological malignancies.
Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, et al · · 2012 · cited 50× · PMID 22710665 · DOI 10.1038/nrurol.2012.117 -
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.
Yu M, Yang W, Yue W, Chen Y. · · 2022 · cited 35× · PMID 36257824 · DOI 10.1002/advs.202204335 -
PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs.
Wadelin FR, Fulton J, Collins HM, Tertipis N, et al · · 2013 · cited 23× · PMID 23460923 · DOI 10.1371/journal.pone.0058052 -
PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.
Gelmi MC, Gezgin G, van der Velden PA, Luyten GPM, et al · · 2023 · cited 20× · PMID 38149971 · DOI 10.1167/iovs.64.15.36
Verify or expand the search:
- PubMed search for NCT01159964
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer, Non-Small Cell
Currently open trials in the same condition.
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT06405230 — Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Or · Phase 1, PHASE2 · recruiting
- NCT07166003 — Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer · recruiting
- NCT06942845 — Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre · active not recruiting
- NCT06687408 — Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques · recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01159964 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 18 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01159964.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing